DoD Prostate Cancer, Health Disparity Research Award | W81XWH 22 PCRP HDRA

Opportunity Information: Apply for W81XWH 22 PCRP HDRA

The DoD Prostate Cancer Research Program (PCRP) Health Disparity Research Award (FY22) is a competitive research funding opportunity designed to support innovative, high-impact projects aimed at reducing and ultimately eliminating prostate cancer health disparities. The central goal is to generate knowledge or interventions that can meaningfully improve outcomes across the full disease and care continuum, including disparities in incidence, morbidity, mortality, and survivorship. The program is intentionally broad in the kinds of science it will consider, encouraging applications ranging from basic and mechanistic work to translational, clinical, population, behavioral, and health services research, as long as the work is clearly anchored in the problem of inequity in prostate cancer burden and outcomes.

A key expectation is that the proposed project directly aligns with one or more of the FY22 Health Disparity Research Award Focus Areas, and applicants must explicitly explain that connection in the application. If a project does not neatly fit a listed Focus Area, it can still be considered, but only if the applicant makes a persuasive case that the work targets another critical contributor to prostate cancer disparities and that it fits within the FY22 PCRP Overarching Challenges. In other words, applicants need to do more than describe a general prostate cancer study; they must clearly articulate why the research matters specifically for disparity reduction and how it advances the program priorities.

The award places heavy emphasis on real-world impact and a credible pathway to follow-on development. Reviewers are looking for research that could substantially shift understanding of disparity drivers (for example, biological, social, structural, environmental, or health-system factors) or lead to practical advances that reduce unequal outcomes. Innovation is strongly valued, with the logic that novel approaches may offer greater leverage against stubborn inequities. Importantly, applications must include a detailed transition plan describing what happens after the award ends, including how findings will be moved to the next stage of development and kept on track toward clinical or public health impact, even if the funded work itself is not the final step before implementation.

In terms of allowable scope, the program supports basic, translational, and clinical research, including clinical trials, but it draws a line at scale and stage. Only small, early-stage clinical trials are permitted, up to and including phase 2 (or equivalent). Applicants proposing trials are encouraged to use the PCRP Prostate Cancer Clinical Trials Consortium to help start and complete trials efficiently. Preliminary data are welcomed but not required, and any unpublished preliminary data included should come from the PI or members of the research team rather than outside groups.

Because disparity research often involves comparing outcomes across populations, the opportunity highlights methodological care when studying the biological basis of disparity. Applicants are encouraged to think critically about how they define and stratify populations, particularly when choosing between genetic or genomic classifications versus self-reported race, and to justify that choice clearly. The program also requires a strong statistical plan, including a complete power analysis, to show the sample size is appropriate for the study aims and that the design can support defensible conclusions rather than underpowered or ambiguous results.

The solicitation also signals expectations around research rigor and reproducibility, especially for preclinical work. Investigators are encouraged, where relevant, to authenticate cell lines, apply strong statistical practices in animal experiments, and include experiments that strengthen clinical relevance and translatability. When projects rely on special resources (data sets, specimens, patient populations, core facilities, consortium access), applicants are encouraged to document access and availability through letters of support, helping reviewers assess feasibility and the likelihood the work will stay on schedule.

Community engagement is a major theme. When appropriate for the research question, investigators are strongly encouraged to involve members of the targeted community or population in both development and implementation of the study. Projects that rely on partnerships with community-based or population-based organizations should demonstrate that partnership concretely, typically via letters of support that describe the level and nature of involvement. The opportunity even provides a non-exhaustive list of potential resources and advocacy or community organizations that applicants may use to build collaborations, recruit participants, or improve cultural fit and trustworthiness of the research.

The award includes a New Investigator category meant to bring early-career scientists into prostate cancer health disparity research. This track is structured to support investigators who are early in faculty appointments or building independence, but it comes with added collaboration expectations. New Investigator applications must include one or more collaborators with demonstrated experience in prostate cancer health disparity research, backed by prior funding and publications. Applicants must describe how the collaboration will work, why it is likely to succeed, and how it meaningfully augments the PI's expertise, and they are strongly encouraged to include a letter of collaboration that spells out the collaborator's role.

From an administrative standpoint, awards may be issued as either grants or cooperative agreements, depending on the anticipated level of DoD involvement during performance. If the agency expects no substantial involvement, the mechanism is typically a grant; if the agency expects substantial involvement such as collaboration, participation, or intervention in the research, the mechanism is a cooperative agreement. The final mechanism and the start date are determined during award negotiation, and the award documentation will specify any substantial involvement when applicable.

The opportunity is tied to broader DoD cancer priorities, including interest in accelerating clinical and translational research relevant to advanced and recurrent disease, reflected in references to the congressionally mandated Metastatic Cancer Task Force recommendations. At the same time, the program requires relevance to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public. Collaborations between military or Veteran institutions and non-military institutions are strongly encouraged, with the idea that partnerships can combine infrastructure and access to unique clinical populations, improving both scientific value and practical impact.

Funding and scale are clearly defined. Direct costs for the entire period of performance are capped at $900,000 per award. Program-wide, the DoD expected to allocate about $7.2 million total to fund approximately six applications. As with most federal competitions, actual funding depends on federal appropriations, the number and quality of applications received, peer and programmatic review outcomes, and government requirements. The solicitation noted awards would be made no later than September 30, 2023, and that FY22 funds supporting these awards would generally be available for use for a limited period, with an anticipated expiration for use on September 30, 2028.

Finally, the announcement outlines compliance requirements for studies involving humans or animals. Any DoD-funded research involving human subjects, human anatomical substances, or human cadavers must undergo review by the USAMRDC Office of Research Protections, Human Research Protection Office, in addition to local IRB or ethics committee review; local IRB approval is not required at submission, but investigators should plan for the additional DoD review timeline. Multi-institution human studies must include a plan for single IRB arrangements and identify the lead institution responsible for master protocol and consent materials. For clinical trials, funded investigators must comply with federal requirements to post IRB-approved informed consent forms on a public federal website. Animal research similarly requires review by the Animal Care and Use Review Office in addition to local IACUC review, with applicants advised to plan for additional review time. If investigators plan to use DoD or VA resources, databases, or patient populations, they must describe access and provide a plan to maintain that access throughout the project, reinforcing the program's focus on feasibility as well as impact.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Health Disparity Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 04, 2022.
• Applicants must submit their applications by Aug 25, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PCRP HDRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: